FDA Approved: GAVRETO — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

Genentech filed a supplemental application for Gavreto (pralsetinib) with the FDA. The action seeks a label update that could expand indications to RET fusion-p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Thyroid Cancer

Drugs mentioned

• GAVRETO (pralsetinib)

Snippet

SUPPL AP for GAVRETO (PRALSETINIB)